View Older Stories View More Recent Stories

May 23, 2024 07:03PM FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option
May 23, 2024 07:05AM Guardant Health (GH) Reports FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening
May 23, 2024 07:05AM Guardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening
May 22, 2024 04:05PM Guardant Health to Participate in Upcoming Investor Conferences
May 21, 2024 08:06AM Guardant Health (GH) Receives EU IVDR Certification for Guardant360 CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications
May 21, 2024 08:05AM Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications
May 17, 2024 08:05AM Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 16, 2024 08:05AM Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week
May 9, 2024 04:05PM Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
May 7, 2024 04:05PM Guardant Health to Participate in Upcoming Investor Conferences
May 7, 2024 08:00AM Guardant Health Surpasses 500 Peer-Reviewed Publications Milestone
Apr 22, 2024 08:54AM Guardant Health (GH) Announces FDA Advisory Panel Review of Shield Blood Test to Screen for Colorectal Cancer to Be Held on May 23
Apr 22, 2024 08:52AM FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23
Apr 18, 2024 04:05PM Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024
Apr 3, 2024 08:05AM Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting
Mar 13, 2024 05:00PM Guardant Health (GH) Announces Publication of ECLIPSE Study Data
Mar 13, 2024 05:00PM Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine
Mar 1, 2024 05:30AM New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap
Feb 22, 2024 04:05PM Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
Feb 15, 2024 04:05PM Guardant Health to Participate in Upcoming Investor Conferences
Feb 1, 2024 04:05PM Guardant Health to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
Jan 17, 2024 08:05AM Guardant Health to present data at ASCO GI supporting use of liquid biopsy to predict colon cancer recurrence
Jan 8, 2024 09:05AM Guardant Health (GH) Announces Preliminary Fourth Quarter and Full Year 2023 Results
Jan 8, 2024 09:00AM Guardant Health Announces Preliminary Fourth Quarter and Full Year 2023 Results
Jan 8, 2024 02:30AM Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
Jan 2, 2024 11:00AM Guardant Health Appoints Terilyn Juarez Monroe as Chief People Officer
Dec 21, 2023 09:00AM Guardant Health (GH) Announces 3.39M Share Offering at $26.77/sh
Dec 21, 2023 09:00AM Guardant Health Announces $90.7 Million Registered Direct Offering with Baillie Gifford
Dec 20, 2023 04:05PM Guardant Health to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Dec 19, 2023 04:06PM Guardant Health (GH) Announces Tentative Date of FDA Advisory Panel Review of Shield Blood Test
Dec 19, 2023 04:05PM Guardant Health Announces Tentative Date of FDA Advisory Panel Review of Shield™ Blood Test
Dec 4, 2023 05:00AM Cancer Research UK and Guardant Health Launch Collaboration to Advance Cancer Research and Clinical Development Activities
Nov 30, 2023 08:05AM Guardant Health to present data at San Antonio Breast Cancer Symposium demonstrating utility of liquid biopsy in biomarker identification, therapy selection and residual disease detection
Nov 15, 2023 04:05PM Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 15, 2023 04:18AM Guardant Health (GH) to Appeal Federal District Court Verdict
Nov 15, 2023 03:00AM Guardant Health to Appeal Federal District Court Verdict
Nov 6, 2023 04:05PM Guardant Health Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
Nov 3, 2023 08:00AM Guardant Health to Participate in Upcoming November Investor Conferences
Oct 31, 2023 08:05AM Guardant Health, Flatiron Health Announce Integration of Guardant Genomic Profiling Tests Into OncoEMR® Platform
Oct 23, 2023 03:45AM First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer
Oct 16, 2023 04:05PM Guardant Health to Report Third Quarter 2023 Financial Results on November 6, 2023
Sep 6, 2023 08:05AM Guardant Health Receives Coverage for Guardant Reveal™ from Geisinger Health Plan
Sep 5, 2023 08:05AM Guardant Health (GH) Receives Regulatory Approval in Japan for Guardant360 CDx as Companion Diagnostic to ENHERTU
Sep 5, 2023 08:05AM Guardant Health Receives Regulatory Approval in Japan for Guardant360® CDx as Companion Diagnostic to ENHERTU® for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations
Sep 1, 2023 03:47PM Guardant Health (GH) Provides Update on COBRA Study, Restates Confidence in MRD Test
Sep 1, 2023 03:46PM Guardant Health Provides Update on COBRA Study, Restates Confidence in MRD Test
Aug 31, 2023 04:05PM Guardant Health to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Aug 17, 2023 04:05PM Guardant Health to Host Investor Day on September 7, 2023
Aug 3, 2023 04:05PM Guardant Health Reports Second Quarter 2023 Financial Results and Increases Revenue Guidance
Aug 1, 2023 04:05PM Guardant resolves pending litigation with Illumina and enters into new agreement to advance long-term commercial partnership and cancer research
View More Recent Stories View Older Stories